Using larynx stimulation to treat chronic cough
Vibrotactile Stimulation of the Larynx to Treat Unexplained Chronic Cough
This study is testing a new way to help adults with chronic cough feel better by using gentle vibrations on their voice box to see if it reduces their coughing.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 88 Years |
| Sex | All |
| Sponsor | University of Minnesota Academic / other |
| Locations | 1 site (Minneapolis, Minnesota) |
| Trial ID | NCT05273190 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effects of non-invasive vibrotactile stimulation on the larynx to alleviate symptoms of unexplained chronic cough. Participants will undergo treatment aimed at reducing cough severity, measured through a visual analogue scale. The study focuses on adults who have experienced chronic cough for more than eight weeks and have a significant cough severity rating. The approach is designed to be safe and effective for eligible individuals.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18-88 who have been experiencing unexplained chronic cough for over eight weeks.
Not a fit: Patients with electronic implants, those currently undergoing speech therapy for cough, or individuals with certain medical conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly reduce the severity of chronic cough in patients who have not found relief through traditional methods.
How similar studies have performed: While this approach is innovative, there is limited existing research on the effectiveness of vibrotactile stimulation for chronic cough, making this a novel investigation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged 18-88 * \>8 weeks of cough * Cough visual analogue scale (VAS): Rating of 30 or greater on a 0-100 cough severity scale * Ability to provide informed consent and independently complete questionnaires * Ability to read and speak English Exclusion Criteria: * Electronic implants (e.g., pacemaker) * Currently doing speech therapy for cough * Contraindications to safe or effective VTS device use * No regular access to wifi internet Neuromuscular impairment that may affect cough/laryngeal sensation and/or function (e.g., multiple system atrophy, Parkinson, CVA, vocal fold paralysis or paresis) * Untreated carotid disease * BMI \> 40 (for transmission of VTS through soft tissue) * Current or recent (quit \< 3 months ago) smoking * Known currently infectious cause for cough (e.g., TB, pertussis, COVID) * History of known or suspected aspiration pneumonia * Diagnosis or clinical suspicion of chronic obstructive pulmonary disease (COPD) * Diagnosis or clinical suspicion of interstitial lung disease (ILD) * Unmanaged reflux * Unmanaged allergies/postnasal drip
Where this trial is running
Minneapolis, Minnesota
- University of Minnesota — Minneapolis, Minnesota, United States (Recruiting)
Study contacts
- Principal investigator: Stephanie Misono — University of Minnesota
- Study coordinator: Clinical Research Coordinators Ashley Ramaker, MS or colleagues
- Email: coughstudy@umn.edu
- Phone: 612-625-3278
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.